Novartis' Cosentyx Goes Head-To-Head With Humira
With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.
With the initiation of EXCEED and SURPASS, Novartis is aiming to challenge Humira’s status as the preferred first-line biologic for ankylosing spondylitis and psoriatic arthritis.